MAPT and Alzheimer disease: A N-terminal truncated fragment of tau, broadly defined as the N-terminal part of tau combined with the proline-rich region and devoid of the repeat domain and C-terminus [16, 99, 130], is now a well-established biomarker that aids in the current set-up of new clinical criteria for AD diagnosis.